Hawk70 again I don’t know who this Roch is
Simple so you don’t get confused:
AGN doing phase 2 for Stroke only
NYR doing phase 1 study for stroke and traumatic brain injury. As per company announcements its next quarter and fully funded for it
Both drugs work by inhibiting calcium influx into the brain which calcium is cytotoxic in large quantities. Both drugs are revolutionary and if one succeeds the other is likely to follow.
NYR 6 million market cap
AGN 110 million market cap
I own both but the return of investment for NYR about to dose the first human and the upside for both Traumatic brain injury and Stroke is right now significantly larger. AGN in phase 2 success end of next year will put this at a billion dollar plus market cap as per CEO interviews. The upside for both companies are significant
AGN Media thread, page-107
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.0¢ |
Change
0.020(2.53%) |
Mkt cap ! $102.9M | |||
| Open | High | Low | Value | Volume |
| 83.5¢ | 84.0¢ | 80.5¢ | $129.5K | 155.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12069 | 80.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 31441 | 1 |
View Market Depth
| Last trade - 15.59pm 09/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |